CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial

Neurology

Volumn 71, Issue 12, 2008, Pages 917-924

  Viglietta, V ^a   Bourcier, K ^b   Buckle, G J ^a   Healy, B ^a   Weiner, H L ^a   Hafler, D A ^a   Egorova, S ^c   Guttmann, C R G ^c   Rusche, J R ^d   Khoury, S J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ITN (Immune Tolerance Network)   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d REPLIGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD28 ANTIGEN; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; MYELIN BASIC PROTEIN; RG 2077; TRYPTOPHAN; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL TENDERNESS; AMINO ACID BLOOD LEVEL; ANXIETY; ARTICLE; BACKACHE; BLURRED VISION; BODY TEMPERATURE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DENDRITIC CELL; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HAND PARESTHESIA; HEART PALPITATION; HEAVINESS; HUMAN; HUMAN CELL; HYPERESTHESIA; HYPESTHESIA; IMMUNOLOGICAL MONITORING; IMMUNOMODULATION; INTERFERON PRODUCTION; LEG DISEASE; LEUKOCYTURIA; LIMB PAIN; LUNG CONGESTION; LYMPHADENOPATHY; LYMPHOCYTE COUNT; MULTIPLE DRUG DOSE; MULTIPLE SCLEROSIS; MUSCLE CRAMP; NAUSEA; NIGHT SWEAT; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PARESTHESIA; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RESTLESS LEGS SYNDROME; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SWEATING; T LYMPHOCYTE; TH0 CELL; TH1 CELL; TH2 CELL; THROMBOCYTE COUNT; TONSIL DISEASE; TREATMENT DURATION; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY HESITANCY; URINARY TRACT INFECTION; VISUAL FIELD DEFECT; WEAKNESS; BRAIN; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNE SYSTEM; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

BRAIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNE SYSTEM; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELIN BASIC PROTEINS; TIME FACTORS;

EID: 54049093695     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000325915.00112.61     Document Type: Article

References (34)

1. Martin R, Gran B, Zhao Y, et al. Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease. J Autoimmun 2001; 16:187-192.
2. Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Annu Rev Neurosci 2002;25:491-505.
3. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. J Immunol 1991;147: 2461-2466.
4. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992;356:607-609.
5. Perrin PJ, Maldonado JH, Davis TA, June CH, Racke MK. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J Immunol 1996;157:1333-1336.
6. Krummel MF, Allison JP. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-2540.
7. Cross AH, Girard TJ, Giacoletto KS, et al. Long-term inhibition of murine experimental autoimmune encephalomyelitis using CTLA-4-Fc supports a key role for CD28 costimulation. J Clin Invest 1995;95:2783-2789.
8. Perrin PJ, Scott D, Quigley L, et al. Role of B7:CD28/ CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J Immunol 1995; 154:1481-1490.
9. Khoury SJ, Akalin E, Chandraker A, et al. CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol 1995;155:4521-4524.
10. Miller SD, Vanderlugt CL, Lenschow DJ, et al. Blockade of CD28/B7-1 interaction prevents epitope spread- ing and clinical relapses of murine EAE. Immunity 1995;3:739-745.
11. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/ Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995;80:707-718.
12. Vanderlugt CL, Karandikar NJ, Lenschow DJ, Dal Canto MC, Bluestone JA, Miller SD. Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. J Neuroimmunol 1997;79:113-118.
13. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-1227.
14. Schaub M, Issazadeh S, Stadlbauer TH, Peach R, Sayegh MH, Khoury SJ. Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 1999;96:158-166.
15. Chandraker A, Azuma H, Nadeau K, et al. Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest 1998;101: 2309-2318.
16. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997;94:8789-8794.
17. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
18. Lin H, Bolling SF, Linsley PS, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
19. Weber CJ, Hagler MK, Chryssochoos JT, et al. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant 1997;6:505-508.
20. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-1101.
21. Moreland LW, Alten R, Van den Bosch F, et al. Costimula-tory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002;46: 1470-1479.
22. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271.
23. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-1252.
24. Abrams JR, Kelley SL, Hayes E, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-694.
25. Wei X, Warfield SK, Zou KH, et al. Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. J Magn Reson Imaging 2002;15:203-209.
26. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York: John Wiley & Sons, 1999.
27. Team RDC. R: A Language and Environment for Statistical Computing [online]. Available at: http://www. R-project.org. Accessed July 14, 2008.
28. Anderson DE, Bieganowska KD, Bar-Or A, et al. Paradoxical inhibition of T-cell function in response to CTLA-4 blockade: heterogeneity within the human T-cell population. Nat Med 2000;6:211-214.
29. Brown DR, Green JM, Moskowitz NH, Davis M, Thompson CB, Reiner SL. Limited role of CD28-mediated signals in T helper subset differentiation. J Exp Med 1996;184:803-810.
30. Newell KA, He G, Guo Z, et al. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol 1999;163:2358-2362.
31. Lakkis FG, Konieczny BT, Saleem S, et al. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4. J Immunol 1997;158:2443-2448.
32. Onodera K, Chandraker A, Volk HD, et al. Distinct tolerance pathways in sensitized allograft recipients after selective blockade of activation signal 1 or signal 2. Transplantation 1999;68:288-293.
33. Padrid PA, Mathur M, Li X, et al. CTLA4Ig inhibits airway eosinophilia and hyperresponsiveness by regulating the development of Th1/Th2 subsets in a murine model of asthma. Am J Respir Cell Mol Biol 1998;18:453-462.
34. Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today 1999;20:469-473.